1 Min Read
Feb 1 (Reuters) - Scynexis Inc:
* SCYNEXIS PRESENTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF SCY-078 USED IN COMBINATION FOR THE TREATMENT OF ASPERGILLUS INFECTIONS AT AAA 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.